Summary
Amgen Inc. reported relatively flat total revenues for the third quarter of 2017 compared to the prior year, with a slight decrease in product sales offset by an increase in other revenues. Net income also remained stable, but diluted Earnings Per Share (EPS) saw a modest increase due to a reduction in outstanding shares. The company's balance sheet reflects a solid cash position and significant investments in marketable securities. Operating expenses showed a slight increase due to specific charges, but underlying efficiency improvements were noted. Amgen continued its capital return strategy through dividends and share repurchases, demonstrating confidence in future cash flows. The company is navigating patent litigations and biosimilar competition, while also facing operational challenges and expenses related to Hurricane Maria in Puerto Rico.
Financial Highlights
55 data points| Revenue | $5.77B |
| Cost of Revenue | $990.00M |
| Gross Profit | $4.46B |
| SG&A Expenses | $1.17B |
| Operating Expenses | $3.33B |
| Operating Income | $2.44B |
| Interest Expense | $325.00M |
| Net Income | $2.02B |
| EPS (Basic) | $2.78 |
| EPS (Diluted) | $2.76 |
| Shares Outstanding (Basic) | 728.00M |
| Shares Outstanding (Diluted) | 733.00M |
Key Highlights
- 1Total revenues for Q3 2017 were $5.77 billion, a slight decrease of 1% year-over-year, with product sales down 1% to $5.45 billion and other revenues up 8% to $320 million.
- 2Net income for Q3 2017 was $2.021 billion, largely flat compared to $2.017 billion in Q3 2016. Diluted EPS increased by 3% to $2.76, benefiting from a reduction in weighted-average diluted shares.
- 3Operating expenses increased by 2% to $3.33 billion, primarily due to charges related to discontinuing the development of AMG 899 and restructuring efforts, partially offset by savings from process improvements.
- 4The company's cash and cash equivalents and marketable securities totaled $41.35 billion as of September 30, 2017, providing strong liquidity.
- 5Amgen returned $2.53 billion to shareholders through dividends and $2.37 billion through stock repurchases during the first nine months of 2017.
- 6The company is actively involved in various patent litigations, including those related to PCSK9 antibody, Sensipar®, and KYPROLIS®.
- 7Amgen incurred $67 million in pre-tax expenses related to Hurricane Maria in Puerto Rico during Q3 2017, with additional expenses expected in Q4 2017.